WO2024035268A3 - Tau pathway modulators - Google Patents

Tau pathway modulators Download PDF

Info

Publication number
WO2024035268A3
WO2024035268A3 PCT/QA2023/050016 QA2023050016W WO2024035268A3 WO 2024035268 A3 WO2024035268 A3 WO 2024035268A3 QA 2023050016 W QA2023050016 W QA 2023050016W WO 2024035268 A3 WO2024035268 A3 WO 2024035268A3
Authority
WO
WIPO (PCT)
Prior art keywords
tau
pathway modulators
modulators
pathway
methods
Prior art date
Application number
PCT/QA2023/050016
Other languages
French (fr)
Other versions
WO2024035268A2 (en
Inventor
Nasser Hussein Zawia
Original Assignee
Qatar Foundation For Education, Science And Community Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qatar Foundation For Education, Science And Community Development filed Critical Qatar Foundation For Education, Science And Community Development
Publication of WO2024035268A2 publication Critical patent/WO2024035268A2/en
Publication of WO2024035268A3 publication Critical patent/WO2024035268A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Pharmaceutical compositions and methods for treating tauopathies are provided.
PCT/QA2023/050016 2022-08-10 2023-08-09 Tau pathway modulators WO2024035268A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263396855P 2022-08-10 2022-08-10
US63/396,855 2022-08-10

Publications (2)

Publication Number Publication Date
WO2024035268A2 WO2024035268A2 (en) 2024-02-15
WO2024035268A3 true WO2024035268A3 (en) 2024-03-21

Family

ID=89852244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/QA2023/050016 WO2024035268A2 (en) 2022-08-10 2023-08-09 Tau pathway modulators

Country Status (1)

Country Link
WO (1) WO2024035268A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234384A1 (en) * 2007-03-19 2008-09-25 Xenon Pharmaceuticals Inc. Biaryl and biheteroaryl compounds useful in treating iron disorders
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
KR101830838B1 (en) * 2015-07-02 2018-02-22 이화여자대학교 산학협력단 Pharmaceutical composition comprising peptidomimetic compounds for preventing and treating rheumatoid arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902330B2 (en) * 2004-02-13 2011-03-08 Albert Einstein College Of Medicine Of Yeshiva University Protein kinase inhibitors and methods for identifying same
US20080234384A1 (en) * 2007-03-19 2008-09-25 Xenon Pharmaceuticals Inc. Biaryl and biheteroaryl compounds useful in treating iron disorders
KR101830838B1 (en) * 2015-07-02 2018-02-22 이화여자대학교 산학협력단 Pharmaceutical composition comprising peptidomimetic compounds for preventing and treating rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem ANONYMOUS : "2-(Phenylthio)-benzoic Acid", XP093150836 *

Also Published As

Publication number Publication date
WO2024035268A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
Kugaji et al. Effect of Resveratrol on biofilm formation and virulence factor gene expression of Porphyromonas gingivalis in periodontal disease
EP3914604A4 (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
NO20074100L (en) Microplants for ocular administration
WO2020086747A3 (en) Ssao inhibitors and uses thereof
WO2022031952A3 (en) Treatments for cancers having kras mutations
EP4134366A4 (en) 3-azabicycloalkyl derivative and pharmaceutical composition containing same
MX2021013010A (en) Compositions and methods for modulating complement activity.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2024035268A3 (en) Tau pathway modulators
EP3964520A4 (en) Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising same as active ingredient
MX2022011576A (en) Nlrp3 modulators.
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
WO2023240253A3 (en) Modulators of tnf-alpha activity
EP4083037A4 (en) Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same
WO2022032073A3 (en) Trpml modulators
WO2020257460A3 (en) Apj modulators and uses thereof
WO2021118930A3 (en) Anti-pd-l1 antibody formulations
TW202421627A (en) Akt1 modulators
EP3964218A4 (en) Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient
WO2020251794A3 (en) Compositions and methods for modulating cognitive behavior
FR3093427B1 (en) COMPOSITION FOR USE IN THE PREVENTION AND / OR TREATMENT OF DYSBIOSIS
AU2023902710A0 (en) Pharmaceutical compositions and methods
AU2022903010A0 (en) Pharmaceutical compositions and methods
WO2021118924A3 (en) Compositions and methods for the prevention and treatment of hearing loss
WO2023205783A3 (en) Oral cannabinoid pharmaceutical compositions and methods of treating inflammatory gastrointestinal disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853121

Country of ref document: EP

Kind code of ref document: A2